Suppr超能文献

血管紧张素 II 的真实世界应用及文献复习。

Angiotensin II-Real-Life Use and Literature Review.

机构信息

Department of Anaesthesiology, Intensive Therapy and Pain Management, University Medical Centre Maribor, 2000 Maribor, Slovenia.

Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.

出版信息

Medicina (Kaunas). 2024 Sep 11;60(9):1483. doi: 10.3390/medicina60091483.

Abstract

Angiotensin II is a recently introduced vasopressor, which has been available since 2017. The novelty and the relatively high cost of angiotensin II currently limit its broader application. It induces vasoconstriction by activating the renin-angiotensin-aldosterone system and is currently the sole vasopressor functioning through this pathway. Beyond vasoconstriction, angiotensin II also affects various other physiological processes. Current evidence supports its use in managing vasoplegic and cardiogenic shock in patients who are unresponsive to catecholamines and vasopressin. However, due to limited data, the optimal timing for initiating therapy with angiotensin II, strategies for combining it with other vasopressors, and strategies for its discontinuation remain unclear. Ongoing and planned studies aim to address some of these uncertainties. This article reviews the physiological and pathophysiological effects of angiotensin II, describes its pharmacology, and provides a narrative review of the current literature.

摘要

血管紧张素 II 是一种最近推出的血管加压药,自 2017 年以来已上市。血管紧张素 II 的新颖性和相对较高的成本目前限制了其更广泛的应用。它通过激活肾素-血管紧张素-醛固酮系统引起血管收缩,目前是唯一通过该途径发挥作用的血管加压药。除了血管收缩,血管紧张素 II 还影响其他各种生理过程。目前的证据支持在对儿茶酚胺和血管加压素无反应的患者中,将其用于治疗血管扩张性和心源性休克。然而,由于数据有限,血管紧张素 II 治疗的最佳起始时机、与其他血管加压药联合使用的策略以及停药策略仍不清楚。正在进行和计划中的研究旨在解决其中的一些不确定性。本文综述了血管紧张素 II 的生理和病理生理学作用,描述了其药理学,并对当前文献进行了叙述性综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4ac/11433685/fa460e8f983e/medicina-60-01483-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验